PEB Financials: Results, Ratios & Statements | Pacific Edge

PEB

Pacific Edge

Pharmaceuticals, Biotechnology & Life Sciences

Pacific Edge is a global cancer diagnostics company focused on developing and commercializing bladder cancer diagnostic and prognostic tests. Their key product, Cxbladder, is a suite of non-invasive genomic urine tests used for risk stratification, rule-out, and surveillance of urothelial bladder cancer. The company operates directly in New Zealand, Australia, Singapore, and the United States, and through distributors in other regions.

Short position

short percentage0.09%

reported shorts1.1M

shares on issue1.242B

Pacific Edge (ASX:PEB) has 0.09% of its shares on issue reported as short positions as of 5 Oct 2026, or about 1,063,942 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. PEB is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

Latest result

Year to 31 Mar 2026 (FY26) vs FY25, figures in NZD, the reporting currency

Revenue: 11.5Mvs 21.8M (FY25); Yahoo Finance, as at 29 Sep 2026
NPAT: −35.8Mvs −29.9M (FY25); Yahoo Finance, as at 29 Sep 2026
EPS (diluted): −0.038vs −0.037 (FY25); Yahoo Finance, as at 29 Sep 2026

Rev YoY: −47.4%FY
EPS YoY: n/aTTM

Summary of Annual Report 2026, 25 Jun 2026

Pacific Edge Limited reported an operating revenue of $11.5 million for FY26, a 47.4% decrease, and a net loss after tax of $35.8 million, which widened by 19.5%. No dividend was declared. The company anticipates a return to growth in the new financial year, expecting a crucial Medicare policy to be finalised by the end of calendar year 2026, accelerating test adoption.

Automated summary of the filing; the filing itself is the record.

Key ratios

Year to 31 Mar 2026 (FY); balance sheet at 31 Mar 2026; prices to 9 Oct 2026

Gross margin: 100.0%
Operating margin: −339.7%
Net margin: −311.1%
FCF margin: −278.9%
ROE: −194.7%
ROA: −131.0%
FCF conversion: n/a
Net cash (excl. leases): NZD 7.8M
Net debt / EBITDA: n/a
Current ratio: 2.0×
Interest cover: n/a
Cash dividends paid / net profit: n/a
Market cap: $194.3M
P/E: n/a (reports in NZD)
P/B: n/a (reports in NZD)

Ratios use the reporting currency (NZD); market cap is in AUD. Source: Yahoo Finance, as at 29 Sep 2026.

Financial statements

Figures in NZD, the reporting currency; Yahoo Finance unless marked

PEB income, newest period first, figures in NZD
Line item	FY26	FY25	FY24	FY23
Revenue	11.5M	21.8M	23.9M	19.6M
Gross profit	11.5M	21.8M	23.9M	19.6M
Operating income	−39.1M	−34.1M	−36.8M	−33.5M
EBITDA	−37.0M	−31.8M	−34.0M	−32.8M
EBIT	−39.1M	−34.1M	−36.8M	−33.5M
Pretax income	−35.8M	−29.9M	−29.5M	−27.0M
Tax	0	0	0	0
NPAT	−35.8M	−29.9M	−29.5M	−27.0M
Net interest income	500.0K	1.9M	3.4M	2.7M
EPS basic	−0.038	−0.037	−0.036	−0.033
EPS diluted	−0.038	−0.037	−0.036	−0.033
Shares	1.02B	811.9M	811.3M	810.4M

Financial reports

The company's own filings, newest first

Showing 10 of 15 reports